Business Context and Reporting Period
This Form 8-K, dated August 26, 2021, reports the completion of a business combination between Aerpio Pharmaceuticals, Inc. (the "Company") and Aadi Bioscience, Inc. ("Aadi"). Following the merger, the Company changed its name to Aadi Bioscience, Inc. and its ticker symbol from "ARPO" to "AADI" on the Nasdaq Capital Market. The combined entity is a clinical-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes.
Key Financial Metrics and Capital Structure
While this filing does not report historical revenue, profit, or cash flow metrics, it details significant capitalization events:
- PIPE Financing: The Company raised $155,000,000 through the sale of 11,852,863 shares of Common Stock to PIPE Investors.
- Reverse Stock Split: A 15-for-1 reverse stock split was effected immediately prior to the merger.
- Post-Merger Share Count: Approximately 20.8 million shares of Common Stock were outstanding immediately following the merger and PIPE financing.
- Ownership Structure (Fully Diluted):
- PIPE Investors: ~55.6%
- Former Aadi Stockholders: ~29.2%
- Former Aerpio Stockholders: ~15.2%
- Contingent Value Rights (CVRs): Former Aerpio stockholders received one CVR for each share held, entitling them to 90% of net proceeds from certain future events under CVR covered agreements.
Material Changes Versus Prior Period
The filing documents a fundamental transformation of the registrant:
- Corporate Identity: The Company changed its name from Aerpio Pharmaceuticals, Inc. to Aadi Bioscience, Inc.
- Business Focus: The primary business shifted from Aerpio's operations to Aadi's clinical-stage oncology pipeline.
- Capitalization: The 15:1 reverse stock split significantly reduced the number of outstanding shares while increasing the per-share price.
- Leadership: The Board of Directors and executive leadership were completely reconstituted. Former Aerpio CEO Joseph Gardner, Ph.D., and CFO Regina Marek were terminated. Neil Desai, Ph.D., was appointed President and CEO, and Lance Thibault was appointed Interim CFO.
Guidance, Outlook, and Management Commentary
This filing does not contain specific financial guidance, revenue forecasts, or management commentary regarding future operating results. However, it outlines the following strategic and operational details:
- Equity Incentives: The Company adopted a 2021 Equity Incentive Plan reserving approximately 31 million pre-split shares (subject to adjustment) and a 2021 Employee Stock Purchase Plan reserving approximately 4.7 million pre-split shares.
- Executive Compensation: CEO Neil Desai received an employment agreement with a $600,000 annual base salary and eligibility for a 60% discretionary bonus. Interim CFO Lance Thibault is engaged via a consulting agreement at $400 per hour.
- Future Filings: The Company intends to file financial statements of the acquired business (Aadi) and pro forma financial information within 71 calendar days of this report.
Important Facts for Investor Verification
- CVR Terms: Verify the specific milestones and "net proceeds" definitions in the Contingent Value Rights Agreement (Exhibit 10.1) to understand the potential upside for former Aerpio shareholders.
- Pro Forma Financials: Await the upcoming filing (within 71 days) for pro forma financial information to assess the combined entity's liquidity and burn rate.
- Equity Dilution: Note that PIPE Investors hold a controlling interest (~55.6%) immediately post-merger.
- Trading Symbol: Confirm trading under the new ticker "AADI" on Nasdaq beginning August 27, 2021.
- Regulatory Status: The Company is an emerging growth company and has elected not to use the extended transition period for new accounting standards.